Aquestive Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Aquestive Therapeutics, Inc. (AQST) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$4.31 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-04.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2021-05-04
- Aquestive Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was -$4.31M.
- Aquestive Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-03-31 was -$13.80M.
- Aquestive Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2019-03-31 was -$20.66M.
- Aquestive Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2018-03-31 was -$891.00K.
- Aquestive Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was -$17.52M.
- Aquestive Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was -$11.27M, a 126.08% decline from fiscal 2018.
- Aquestive Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2018 was $43.22M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2021-03-31 | -$4.31M 10-Q · filed 2021-05-04 | |||
| 2020-12-31 | -$17.52M 10-K · filed 2021-03-09 | |||
| 2020-09-30 | -$32.26M 10-Q · filed 2020-11-04 | |||
| 2020-06-30 | -$23.90M 10-Q · filed 2020-08-04 | |||
| 2020-03-31 | -$13.80M 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | -$11.27M 10-K · filed 2021-03-09 | |||
| 2019-09-30 | -$39.69M 10-Q · filed 2020-11-04 | |||
| 2019-06-30 | -$38.43M 10-Q · filed 2020-08-04 | |||
| 2019-03-31 | -$20.66M 10-Q · filed 2020-05-05 | |||
| 2018-12-31 | $43.22M 10-K · filed 2020-03-11 | |||
| 2018-09-30 | $46.60M 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | -$6.74M 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | -$891.00K 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |